Kornimate/medical-research-clean huggingface dataset:
self-myofascial release with foam roller in patients with hemophilic ankle arthropathy

Conditions: Hemophilia

Summary: introduction: hemophilic ankle arthropathy is manifested by degenerative functional alterations (deficit of muscle strength, mobility and proprioception) (intra-articular alterations) and chronic pain. myofascial release techniques are used to treat soft tissue adhesions, relieve pain and reduce tissue sensitivity. design. a randomized clinical trial. aimed: to evaluate the safety and effectiveness of a protocol by self-myofascial release with foam roller applied in patients with hemophilic ankle arthropathy. patients: 70 patients with ankle arthropathy will be recruited for inclusion in the study. patients will be recruited in 5 centers, from different regions of spain. intervention: each session will last approximately 15 minutes, with five physiotherapy sessions per week for a period of 3 months. patients will be evaluated at baseline, after the intervention, and after a follow-up period of 3 months. the treatment program includes 11 exercises that must be administered bilaterally. a mobile application will be developed where each patient will be able to observe the exercises to be carried out. measuring instruments and study variables: digital goniometer (ankle range of motion); visual analog scale and pressure algometer (joint pain); haemophilia joint health score (joint status); dynamometer assess (muscle strength); 6-minute walking test (functionality of lower limbs); mobile device (activity record); finger-floor test (muscle flexibility). at the same time, the study will allow to determine joint bleeding caused by applied physiotherapy treatment. expected results: to demonstrate the safety of this physiotherapy technique in patients with hemophilia. likewise, an improvement in ankle pain, functionality and joint motion is expected.


Eligibility criteria:
inclusion criteria: * patients diagnosed with hemophilia a and b disease. * over 18 years. * diagnosed with hemophilic arthropathy of the ankle (by clinical assessment with the hemophilia joint health score). * on prophylactic or on demand treatment with fviii / fix concentrates. exclusion criteria: * patients without ambulation ability. * patients with inhibitors (antibodies to fviii or fix). * patients with neurological or cognitive alterations that impede the comprehension of the questionnaires and physical tests. * not signed the informed consent document.
a study of 2 different formulations of blosozumab (ly2541546) in post menopausal women

Conditions: Osteoporosis, Postmenopausal

Summary: the purpose of this study is to evaluate the tolerability of two different formulations of blosozumab in women who have reached menopause. this study will last approximately 12 weeks for each participant, not including screening. screening is required within 28 days prior to starting the study.


Eligibility criteria:
inclusion criteria: * part a: overtly healthy postmenopausal (pmp) females * part b: pmp women who are currently taking oral bisphosphonates for prevention or treatment of osteoporosis * have a body mass index (bmi) at screening of 19.0 to 35.0 kilogram per square meter (kg/m\^2) exclusion criteria: * have known allergies to blosozumab, its constituents, or related compounds * have an abnormality in the 12-lead electrocardiogram (ecg) * history of breast carcinoma * fracture of a long bone within 1 year of screening * have used teriparatide within 3 years prior to screening
investigating the sma's role in speech and reading fluency in pws with rtms

Conditions: Stuttering, Adult

Summary: the goal of this clinical trial is to study how a part of the brain called the supplementary motor area (sma) is connected to speech and reading fluency in adults who stutter. researchers will use a method called repetitive transcranial magnetic stimulation (rtms) to learn more about this relationship. the main question it aims to answer is: -will participants' speech and reading fluency improve when we stimulate the sma with rtms? participants will take part in both placebo rtms and real rtms sessions. participants will: * come to the research center for 2 days, with at least a one-week break between visits * read 4 passages and speak on 4 topics * be video recorded while doing these tasks


Eligibility criteria:
inclusion criteria: * to be over 18 years of age * presence of developmental stuttering * being right hand dominant exclusion criteria: * being under 18 years of age * the presence of a diagnosed brain lesion * presence of intracranial metal implantation * presence of a speech and language problem other than stuttering * the presence of a diagnosed neurological disorder * the presence of a diagnosed psychiatric disorder * use of drugs and substances that may affect the central nervous system * history of epilepsy

Keywords: rtms stuttering sma
dietary intake, eating behavior, physical activity level and their relationships with glycemic and weight control in hong kong chinese type 2 diabetic patients

Conditions: Type 2 Diabetes Mellitus in Obese

Summary: the objective of this study is to describe and examine the dietary intake, eating behavior and physical activity level of a cohort of hong kong chinese with t2dm and their association with weight and glycemic control at baseline and 1 year follow-up. the investigators hypothesize that hong kong chinese t2dm patients with unhealthy dietary intake and pattern and low physical activity level are associated with poorer glycemic and weight control, and there will be no improvement with weight and glycemic control under usual care after 1 year.


Eligibility criteria:
inclusion criteria: 1. male or female of chinese ethnicity 2. diagnosis of t2dm 3. able to read chinese and give informed written consents exclusion criteria: 1. type 1 diabetes mellitus 2. end-stage renal failure requiring dialysis or chronic kidney disease (ckd) stage 4 or above 3. malignancy diagnosed within 3 years 4. pregnancy or lactation 5. any medical illness or condition as judged by the investigators as ineligible to participate the study
prevalence of dry eyes in diabetics compared to non diabetics

Conditions: Dry Eyes

Summary: the purpose is to compare the prevalence of dry eyes in diabetics and non diabetics. this might help identify a group of patients at greater risk for dry eye complications. diabetics have been shown to have poor ocular surface healing and might benefit from dry eye therapy earlier if they are shown to be at greater risk for dry eyes.

dry eye disease is one of the most common eye problems seen in ophthalmology. diabetics are at high risk for multiple eye problems, including retinopathy and glaucoma. they also have been shown to have poor ocular surface healing. i would like to evaluate the prevalence of dry eye disease in diabetics to see if they are also at greater risk for the known complications of dry eye disease. if so, they might benefit from early intervention.

Eligibility criteria:
inclusion criteria: * 50 patients with diabetes, 25 without diabetes over the age of 40 exclusion criteria: * current use of glaucoma drops or currently within the postoperative period from eye surgery

Keywords: dry eyes diabetes
genetic analysis of patients responsive to ranibizumab but resistant to aflibercept

Conditions: Age-Related Macular Degeneration

Summary: a cohort of patients responsive to treatment with ranibizumab but resistant to aflibercept were identified in a previously conducted retrospective study. identified patients will have their blood drawn for genome wide sequencing. the sequencing data will be compiled and analyzed in an attempt to identify a common genetic basis for patients susceptible to ranibizumab but resistant to aflibercept.

a cohort of patients responsive to treatment with ranibizumab but resistant to aflibercept were identified in a previously conducted retrospective study. identified patients will have their blood drawn for genome wide sequencing. the sequencing data will be compiled and analyzed in an attempt to identify a common genetic basis for patients susceptible to ranibizumab but resistant to aflibercept. blood samples will be drawn for genetic analysis for all patients enrolled in the study. the sample (1 tube- 6ml of blood) will be collected using - 8.5ml paxgene blood dna tubes (http://www.qiagen.com/products/catalog/sample-technologies/dna-sample- technologies/genomic-dna/paxgene-blood-dna-tubes). samples will be stored at -80 until time for analysis. note that some blood draws will be performed at satellite clinics and transported to main facility for storage in -80 freezer. it is the understanding of arc pi and staff that the paxgene blood dna tubes keep samples stable at room temp for 1-2 days. however, staff will transport samples in timely fashion (room temp, on ice, dry ice, etc), to -80 freezer for storage until all samples are collected. once all samples are collected, they will be shipped to genentech for analysis. dna extraction, the generation of genetic data, and subsequent analysis will be performed at genentech or via third party. dna will be assayed for polymorphisms through genome wide snp chip or whole genome sequencing. the subject's genotype or haplotype will be correlated with their visual response and oct response.

Eligibility criteria:
inclusion criteria: * subjects will be eligible if the following criteria are met: * demonstrate worsening of exudation when switched from ranibizumab to aflibercept * ability to provide written informed consent and comply with study assessments for the full duration of the study exclusion criteria: * any other condition that the investigator believes would pose a significant hazard to the subject
sglt2 inhibitors on clinical outcomes and left ventricular remodeling in type 2 diabetic patients with acute myocardial infarction, a prospective, multi-center registry study

Conditions: Myocardial Infarction; Diabetes Mellitus, Type 2

Summary: prospective trials performed on type 2 diabetes patients without established cardiovascular disease has shown that sglt2 inhibitors reduce cardiovascular risk. no studies have yet examined the occurrence of cardiovascular disease in patients with acute myocardial infarction. the investigators designed the current study to evaluate the most ideal oral hypoglycemic agent in type 2 diabetes patients undergoing percutaneous coronary intervention for acute myocardial infarction. the investigators hypothesize that the use of sglt-2 inhibitors will reduce cardiovascular events and modify left ventricular remodeling after myocardial infarctions.

8 hospitals of the catholic university of korea with high-volume percutaneous coronary intervention of following hospitals are participating in the current study. seoul st. mary's hospital, seoul, south korea yeoido st. mary's hospital, seoul, south korea uijongbu st. mary's hospital, gyeonggi-do, south korea eunpyeong st. mary's hospital, seoul, south korea bucheon st. mary's hospital, gyeonggi-do, south korea incheon st. mary's hospital, incheon, south korea st. vincent hospital, gyeonggi-do, south korea daejeon st. mary's hospital, daejeon, south korea after recruitment of all patients, the control group will be selected from a previous prospective cohort (corea-ami, nct02385682) using identical inclusion / exclusion criteria except for use of sglt2 inhibitors. the control cohort of 3,000 patients will be selected using 1:3 propensity matching.

Eligibility criteria:
inclusion criteria: * acute myocardial infarction who were treated with percutaneous coronary intervention * type 2 diabetes mellitus * started sglt2 inhibitors \<1 month before/after pci exclusion criteria: * type 1 diabetes mellitus * insulin / glp-1 analogue users * previous users of sglt2 inhibitors * pregnancy

Keywords: percutaneous coronary intervention sglt-2 inhibitor
innovative stratification of arrhythmic risk (isar-trial): female patients

Conditions: Myocardial Infarction

Summary: the purpose of this study was to investigate differences in risk prediction in female post-infarction patients.


Eligibility criteria:
inclusion criteria: acute myocardial infarction; female gender exclusion criteria: -

Keywords: assessment, risk autonomic nervous system gender
safety study of tipranavir co-administered with low-dose ritonavir (tpv/r) in patients with advanced hiv-1 infection and limited treatment options

Conditions: HIV Infections

Summary: this study evaluated the safety and tolerability of tipranavir to improve treatment options for hiv type 1-infected patients who have been previously treated and whose treatment is no longer effective.

the purpose of this open label study is to assess the safety and tolerability of tipranavir co-administered with low-dose ritonavir (500 mg tipranavir/200 mg ritonavir bid) in hiv-1 infected patients who are triple antiretroviral class experienced with at least two previous pi-containing regimens. the safety assessment will be performed by evaluating: * the frequency of treatment-emergent adverse events (aes) , all serious adverse events (saes), and additional safety laboratory parameters. * the occurrence of pi class-specific aes, such as hemorrhage, dyslipidemia, hepatic events, hyperglycemia, pancreatitis, and rash. the efficacy assessment will be performed by evaluating: * the quantity of hiv-1 rna * the cd4 cell count. study hypothesis: the purpose of this open label study is to assess the safety and tolerability of tipranavir co-administered with low-dose ritonavir (500 mg tipranavir/200 mg ritonavir bid) in hiv-1 infected patients who are triple antiretroviral class experienced with at least two previous pi-containing regimens. comparison(s): n.a.

Eligibility criteria:
inclusion criteria: 1. triple antiretroviral class experienced patients with at least two previous pi-based regimens, who had failed or are intolerant to currently approved hiv-1 treatments 2. age \>= 18 years 3. patient is willing to use an effective barrier method of contraception for the duration of study participation and up to three months thereafter 4. patient voluntarily provides written informed consent to participate, in compliance with local law exclusion criteria: 1. hypersensitivity to active ingredients or any of the excipients in tipranavir or ritonavir 2. required use of restricted medications 3. female patients of childbearing potential who: * have a positive pregnancy test at baseline or * are breast feeding. 4. any medical condition(s) which, in the opinion of the investigator, would interfere with the patient´s ability to participate in or adhere to the requirements of this protocol. 5. use of other investigational drugs, within 30 days prior to tpv/r initiation and for the duration of study participation. 6. hepatic impairment(\*) evidenced by the following baseline laboratory findings: * ast or alt \>5x upper limit of normal (uln) or total bilirubin \>3.5x uln or * ast or alt \>2.5x uln and total bilirubin \>2x uln (\*) patients with liver enzymes outside this range will be restricted from participation in this safety study until more data become available from ongoing phase iii clinical studies.
exoskeleton robotic assisted gait training in spastic stroke post botulinum toxin a injection

Conditions: Spastic Gait; Spastic

Summary: the purpose of this project is to examine and compare the immediate and long-term effects of combined botulinum toxin type a(bont-a) injection with exoskeleton robotic assisted gait training (rabt) in patients with post-stroke stiff-knee gait.

the aim of the study is to evaluate the effects of bont-a combining with overground exoskeleton robot for patients with post-stroke stiff-knee gait. stiff-knee gait (skg) is a common gait pattern in patients after stroke, characterized by limited knee flexion (kf) during the swing phase of walking. botulinum toxin a (bont-a) injection in rectus femoris muscle is considered the gold standard procedure to treat skg. patients with this gait pattern would reduce walking speed, cause toe dragging, compromise the stability of walking, increase risk of falling, and interfere with daily activities. this randomized controlled trial will contribute to the accelerated refinement and development of efficient and effective treatment programs for patients with post-stroke spastic stiff knee gait. the robot-assisted gait training (ragt) has the potential to be an optimal adjunctive therapy following bont-a treatment. combinations of bont-a and rehabilitation training are suggested to optimize the treatment effect for spasticity related disabilities.

Eligibility criteria:
inclusion criteria: * ischemic or hemorrhagic stroke ≥ 3 months * age ≥ 20 years * functional ambulation category ≥4 * affected rectus femoris spasticity (mas between 1+ and 2) * bont-a treatment-naive or treated with bont-a ≥4 months in the affected leg before recruitment * receiving oral muscle relaxants or other medication for spasticity were on a stable dose for≥2 months * can obey simple order exclusion criteria: * pregnant * sensitivity to bont-a * infection of the skin, soft tissue in the injection area * participation in other trials * fixed contractures or bony deformities in the affected leg * previous treatment of the affected leg with neurolytic or surgical procedures (i.e., phenol block, tendon lengthening of transfer, tenotomy, muscle release, arthrodesis) * severe cardiovascular comorbidity (i.e., recent myocardial infarction, heart failure, uncontrolled hypertension, orthostatic hypotension)

Keywords: spasticity stroke rehabilitation botulinum toxin type a injection robot knee
proximal metatarsal osteotomy in correction of hallux valgus

Conditions: Hallux Valgus and Bunion

Summary: the outcomes of the correction of hallux valgus by proximal opening wedge osteotomy

hallux valgus is a common cause of foot pain and deformity in the adult and adolescent population, which often requires surgical treatment when nonsurgical treatments fail. during the past decades, multiple modified procedures and fixation techniques have been described. the most common types of osteotomies of the first metatarsal are crescentic, chevron, scarf and lateral or medial opening wedge techniques. a concern with the chevron and other distal osteotomies is the development of avascular necrosis of the first metatarsal head with a reported incidence of between 0% and 20%. on the other side, the proximal dome osteotomy along with a distal soft tissue release is an excellent procedure. the proximal location of the osteotomy avoids devascularization of the metatarsal head, and the crescent shape maintains the length of the metatarsal. it allows a high degree of correction at the intermetatarsal angle in severe deformities. when the condition is associated with an increased intermetatarsal angle, a surgical technique using a proximal first metatarsal osteotomy is often indicated. a proximal opening wedge osteotomy stabilized with a wedge and plate configuration offers a stable, reliable means to correct the increased intermetatarsal angle. over the past 10 years, some surgeons have increasingly used locking plates instead of a single screw for stabilisation of the osteotomy with the assumption of better postoperative stability and preserved length of the first metatarsal. in addition, fixation with a plate has been described as technically less challenging.

Eligibility criteria:
inclusion criteria: * all admitted patients to assiut university hospitals. * age group of 15 years old and above. * moderate and severe degrees of hallux valgus. exclusion criteria: * burn * age group below 15 years old. * patient who refuse to participate in the study.

Keywords: proximal osteotomy medial opening wedge hallux valgus
effect of qva149 on exercise tolerance in patients with chronic obstructive pulmonary disease (copd)

Conditions: COPD

Summary: this study assessed the effect of once-daily indacaterol and glycopyrronium bromide (qva149) on exercise endurance in patients with moderate to severe chronic obstructive pulmonary disease (copd).


Eligibility criteria:
inclusion criteria: * diagnosis of moderate to severe stable chronic obstructive pulmonary disease (copd) stage ii or stage iii according to the global initiative for chronic obstructive lung disease (gold) guidelines (2009) * qualifying spirometry, forced expiratory volume in one second (fev1) and post-bronchodilator fev1/fvc (forced vital capacity) * smoking history ≥ 10 pack years exclusion criteria: * pregnant women or nursing mothers or women of child-bearing potential not using adequate contraception * cardiac abnormality * history of asthma * contraindications to cardiopulmonary exercise testing * participation in active phase of pulmonary rehabilitation program * history of cancer within the past 5 years other protocol-defined inclusion/exclusion criteria may apply

Keywords: copd qva149 tiotropium exercise exercise tolerance combination bronchodilator moderate to severe copd
rotational stability analysis of a toric monofocal iol

Conditions: Cataract; Lens Opacities; Astigmatism

Summary: this is a single-center, prospective pmcf study whereby patients undergoing routine cataract surgery will have monolateral implantation of hydrophilic monofocal toric intraocular lens ankoris.

this is a single-center, prospective, nonrandomized pmcf study whereby patients undergoing routine cataract surgery will have monolateral implantation of hydrophilic monofocal toric intraocular lens (ankoris). the device under investigation is manufactured by the sponsor of this study. the refractive power of the lens has a spherical and a cylindrical component. the iols will be implanted in the course of routine cataract surgery and will benefit to patients suffering from cataract development and showing pre-existing corneal astigmatism. the primary objective of this study is to determine the rotational stability of the ankoris intraocular lens. the secondary objective is to measure the residual astigmatism after ankoris implantation with respect to the targeted astigmatism correction. in total approx. 20 eyes of 20 patients will be recruited for this clinical study. follow-ups will be performed 1 day, 1 month, and 3 months after cataract surgery. subjects would have the option for unscheduled visits if required medically.

Eligibility criteria:
inclusion criteria: * cataracteous eyes with no comorbidity * regular corneal astigmatism \>1 dioptre and \<3d determined by an automatic keratometer (regularity determined by the topography of the keratometry). * availability, willingness and sufficient cognitive awareness to comply with examination procedures * signed informed consent •\>50 years old exclusion criteria: * acute or chronic disease or illness that would increase risk or confound study results (e.g. diabetes mellitus (with retinopathy), immunocompromised, glaucoma etc...) * any ocular comorbidity * history of ocular trauma or prior ocular surgery including refractive procedures * capsule or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome, marfan's syndrome) * pupil abnormalitis (non-reactive, tonic pupils, abnormally shaped pupils or pupils that do not dilate under mesopic/scotopic conditions)

Keywords: intraocular lens monofocal toric lens